|End-of-Life Care for Hematologic vs Solid-Tumor Patients|
COPENHAGEN, Denmark ― Patients with hematologic malignancies often receive more aggressive care at the end of life compared with patients with solid tumors, according to a recent study conducted at the University of Texas MD Anderson Cancer Center, ...
Medscape - Mon, 20 Jul 2015 04:48
|Home > Current Issue > POINT-COUNTERPOINT: CLL—What's the Best Frontline ...|
At the Great Debates & Updates in Hematologic Malignancies meeting here, the question was debated about the best frontline regimen for a 60-year-old CLL patient who requires therapy: Should it be fludarabine-cyclophosphamide-rituximab (FCR) or the ...
Oncology Times - Thu, 30 Jul 2015 12:03
|Seattle Genetics Reports Second Quarter 2015 Financial Results|
... option to expand the collaboration to include a third ACTR product. Received a milestone payment under a collaboration with AbbVie, triggered by its initiation of a phase 1 trial for an ADC for hematologic malignancies utilizing Seattle Genetics ...
MarketWatch - Thu, 30 Jul 2015 13:05
|KaloBios Announces FDA Clearance of Investigational New Drug Application for ...|
"I am very excited to be able to explore KB003, an anti-GM-CSF agent, as a potential therapeutic for CMML patients given the significant unmet medical need these patients face," said Dr. Eric Padron of the Department of Hematologic Malignancies at H ...
PR Newswire (press release) - Wed, 29 Jul 2015 09:52
|KaloBios Regains Compliance with NASDAQ Minimum Bid Price Requirement|
MarketWatch - Wed, 29 Jul 2015 07:15
|KaloBios' IND application for KB003 gets FDA clearance to treat patients with CMML|
Pharmaceutical Business Review - Thu, 30 Jul 2015 04:26
|Delayed Medicare Reimbursement, Competition Hamper Foundation Medicine's ...|
Earlier this week, Foundation Medicine said it had initiated a large-scale multi-center prospective clinical study to validate its ctDNA test for multiple, solid, and hematologic tumor types. The study will compare results from the blood-based ctDNA ...
GenomeWeb - Thu, 30 Jul 2015 09:41
|Zacks Rating on Infinity Pharmaceuticals, Inc.|
The Companys lead product is a potent, oral inhibitor of Class I PI3K-delta and PI3K-gamma, which the Company is investigating in both hematologic malignancies and inflammatory diseases.Its retaspimycin hydrochloride (HCl), is a potent and selective ...
American Trade Journal - Thu, 30 Jul 2015 03:52
|AbbVie (ABBV) Stock Price Target Raised at Deutsche Bank|
AbbVie announced in March that it was acquiring Pharmacyclics (PCYC) and its flagship asset Imbruvica, a highly effective treatment for hematologic malignancies. "Addition of Imbruvica completely changes the growth profile of the company and helps EPS ...
TheStreet.com - Wed, 29 Jul 2015 08:22
|Spark Therapeutics, Inc. to Host Conference Call on August 5th at 8:30a.m. to ...|
Spark also is establishing a pipeline of gene therapy candidates to treat hematologic disorders and neurodegenerative diseases, including through a global collaboration with Pfizer Inc. around the development and commercialization of its SPK-FIX ...
Nasdaq - Wed, 29 Jul 2015 05:00